Evaluation of Ventilator-Associated Pneumonia According to Stress Related Mucosal Disease Prophylaxis Regimen in the Intensive Care Unit
AbstractBackground: Ventilator-associated pneumonia (VAP) increases the cost of intensive care unit (ICU) treatment and the chance of mortality. Due to the increasing use of proton pump inhibitors (PPI) and H2 receptor inhibitors for stress ulcer prophylaxis, the purpose of the study was to investigate the differences of VAP in two groups of patients receiving PPI or H2 blocker.Methods: In the retrospective cross sectional study, from September 2011 to September 2012, 43 patients who had positive pulmonary cultures (PC) were studied. These patients had a clinical pulmonary infection score (CPIS) ≥6 for more than 48 hours after receiving stress related mucosal diseases prophylaxis (SRMD). Patients whose SRMD prophylaxis was changed within 72 hours before obtaining the PC samples were excluded. Patients were divided into two groups. One group received pantoprazole (20 cases) and the other group received ranitidine (23 cases). Between the groups, age, sex, APACHE II score, predicted mortality, type of used SRMD prophylaxis drug, duration of prophylaxis prior to PC sampling, interval time between ICU admission and VAP manifestation, the type of bacterial causes of VAP, gastrointestinal bleeding, ICU length of stay and actual mortality were compared.Results: The APACHE II score and predicted mortality were higher in the pantoprazole group (P=0.173, 0.167). We found that 30% of the ranitidine group suffered from upper GI bleeding. In the pantoprazole group, 21.74% suffered from upper GI bleeding (P<0.001). Patients receiving ranitidine had a higher mortality rate and a worse prognosis (P< 0.001).Conclusion: Although there were more critically ill patients with a higher predicted mortality in the pantoprazole group, the ranitidine recipients turned out to have a higher mortality rate.
Talaie H, Sabeti S, Mahdavinejad A, Barari B, Kamalbeik S. A survey on microorganisms and their sensitivity by E-Test in ventilator-associated pneumonia at Toxicological-Intensive Care Unit of Loghman-Hakim Hospital. Acta Biomed. 2010; 81(3):210-6.
Husebye E. The pathogenesis of gastrointestinal bacterial overgrowth. Chemotherapy. 2005;51 Suppl 1:1-22.
Berg RD. Bacterial translocation from the gastrointestinal tract. Advances in experimental medicine and biology. 1999; 473:11-30.
Erdogan-Yildirim Z, Burian A, Manafi M, Zeitlinger M. Impact of pH on bacterial growth and activity of recent fluoroquinolones in pooled urine. Res Microbiol. 2011; 162(3):249-52.
Lemasle P, Baud JM. [Value of echo-marking in the surgical treatment of varicose veins (outside the CHIVA treatment)]. Phlebologie. 1992; 45(3):349-55.
Thorens J, Froehlich F, Schwizer W, Saraga E, Bille J, Gyr K, et al. Bacterial overgrowth during treatment with omeprazole compared with cimetidine: a prospective randomised double blind study. Gut. 1996; 39(1):54-9.
Gulmez SE, Holm A, Frederiksen H, Jensen TG, Pedersen C, Hallas J. Use of proton pump inhibitors and the risk of community-acquired pneumonia: a population-based case-control study. Arch Intern Med. 2007; 167(9):950-5.
Laheij RJ, Sturkenboom MC, Hassing RJ, Dieleman J, Stricker BH, Jansen JB. Risk of community-acquired pneumonia and use of gastric acid-suppressive drugs. Jama. 2004; 292(16):1955-60.
Eurich DT, Sadowski CA, Simpson SH, Marrie TJ, Majumdar SR. Recurrent community-acquired pneumonia in patients starting acid-suppressing drugs. Am J Med. 2010; 123(1):47-53.
Bashar FR, Manuchehrian N, Mahmoudabadi M, Hajiesmaeili MR, Torabian S. Effects of ranitidine and pantoprazole on ventilator-associated pneumonia: a randomized double-blind clinical trial. Tanaffos. 2013; 12(2):16-21.
Dellinger RP, Levy MM, Rhodes A, Annane D, Gerlach H, Opal SM, et al. Surviving Sepsis Campaign: international guidelines for management of severe sepsis and septic shock, 2012. Crit Care Med. 2013; 41(2):580-637.
Rahimi Bashar F, Rastgouyhaghi AR, Torabian S, Hajiesmaeili MR, Sedaghat AR, Seifi S, et al. Prevention of Stress Related Mucosal Disease with Intermittent Intravenous Pantoprazole and Ranitidine in Critically Ill Patients. J Pharm Care. 2013; 1(3): 81-84.
Bashar FR, Manuchehrian N, Mahmoudabadi M, Hajiesmaeili MR, Torabian S. Effects of Ranitidine and Pantoprazole on Ventilator-Associated Pneumonia: A Randomized Double-Blind Clinical Trial. Tanaffos. 2013; 12(2):16-21.
Sasaki T, Yamaya M, Yasuda H, Inoue D, Yamada M, Kubo H, et al. The proton pump inhibitor lansoprazole inhibits rhinovirus infection in cultured human tracheal epithelial cells. Eur J Pharmacol. 2005; 509(2-3):201-10.
Ichikawa H, Yoshida N, Takagi T, Tomatsuri N, Katada K, Isozaki Y, et al. Lansoprazole ameliorates intestinal mucosal damage induced by ischemia-reperfusion in rats. World J Gastroenterol. 2004;10(19):2814-7.
Somberg L, Morris J Jr, Fantus R, Graepel J, Field BG, Lynn R, et al. Intermittent intravenous pantoprazole and continuous cimetidine infusion: effect on gastric pH control in critically ill patients at risk of developing stress-related mucosal disease. J Trauma. 2008; 64(5):1202-10.
Offenstadt G, Maury E. Upper gastrointestinal bleeding in severe sepsis. Crit Care Med. 2008; 36(6):1990-1.